CHMP to discuss Avandia

CHMP will meet on Sept. 8 to discuss the ongoing safety review of diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). CHMP said it plans to finalize the review at its regular monthly meeting on Sept. 20-23. In July, an FDA advisory committee was divided between members recommending taking steps to reduce the risks associated with Avandia and those backing withdrawing the drug from the U.S. market. CHMP is part of the European Medicines Agency (EMA). ...